PharmaRadar360

PharmaRadar360

🇺🇸·1d agoRegulatory

Statistical Considerations for the Design of Rare Disease Clinical Investigations; Establishment of a Public Docket; Request for Information and Comments

The Food and Drug Administration (FDA, the Agency, or we) is establishing a public docket to collect...

Publisher

F
Federal Register

USA

This page provides a limited summary, publisher metadata, and related coverage to support discovery before sending readers to the original article.

Read original

At a glance

Publisher
Federal Register
Region
USA
Scope
Regulatory
Published
September 15, 2026
Language
EN

Publisher context, original article off-platform

This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.

Summary excerpt

The Food and Drug Administration (FDA, the Agency, or we) is establishing a public docket to collect...

Source route

Continue on federalregister.gov

Leave the platform to read the original full article on the publisher site.

Source: Federal Register

Scope: Regulatory

Open original article
Statistical Considerations for the Design of Rare Disease Clinical Investigations; Establishment of a Public Docket; Request for Information and Comments | PharmaRadar360